​

Amicus Therapeutics (FOLD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

FOLD Stock Forecast

Amicus Therapeutics (FOLD) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $15.00, with a high of $15.00 and a low of $15.00. This represents a 53.37% increase from the last price of $9.78.

$9 $10 $11 $12 $13 $14 $15 High: $15 Avg: $15 Low: $15 Last Closed Price: $9.78

FOLD Stock Rating

Amicus Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 0 Hold (0.00%), 1 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 0 6 Strong Sell Sell Hold Buy Strong Buy

FOLD Price Target Upside V Benchmarks

TypeNameUpside
StockAmicus Therapeutics53.37%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$15.67
Last Closing Price$9.78$9.78$9.78
Upside/Downside--60.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25183--12
Jan, 25193--13
Dec, 24293--14
Nov, 24392--14
Oct, 24592--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 17, 2024Tazeen AhmadBank of America Securities$15.00$12.0324.69%53.37%
May 14, 2024Debjit ChattopadhyayGuggenheim$13.00$9.0443.81%32.92%
May 09, 2024Jeffrey HungMorgan Stanley$19.00$9.48100.42%94.27%
Dec 19, 2023Jeffrey HungMorgan Stanley$20.00$12.6657.98%104.50%
May 10, 2021Salveen RichterGoldman Sachs$14.00$9.3949.09%43.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024Cowen & Co.BuyBuyhold
Oct 17, 2024Bank of America SecuritiesBuyBuyhold
Oct 11, 2024JefferiesBuyBuyhold
Sep 06, 2024JefferiesBuyinitialise
Jul 22, 2024Cowen & Co.BuyBuyhold
May 30, 2024Wells FargoOverweightinitialise
May 14, 2024UBSBuyBuyhold
May 14, 2024GuggenheimBuyupgrade
May 09, 2024Morgan StanleyUnderweightUnderweighthold
Dec 19, 2023Morgan StanleyOverweightupgrade

Financial Forecast

EPS Forecast

$-550 $-430 $-310 $-190 $-70 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.07$-0.92$-0.82$-513.56-----
Avg Forecast$-1.02$-0.78$-0.77$-0.45$-0.21$0.13$0.46$0.97$1.45
High Forecast$-1.07$-0.82$-0.81$-0.48$-0.27$0.09$0.33$0.86$1.41
Low Forecast$-0.98$-0.75$-0.75$-0.42$-0.12$0.18$0.76$1.06$1.48
Surprise %4.90%17.95%6.49%114024.44%-----

Revenue Forecast

$250M $440M $630M $820M $1B $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$260.89M$305.51M$329.23M$399.36M-----
Avg Forecast$261.00M$307.12M$327.45M$398.70M$528.08M$637.75M$785.14M$983.63M$1.18B
High Forecast$252.63M$297.27M$319.04M$398.62M$518.07M$625.65M$781.02M$971.13M$1.16B
Low Forecast$270.11M$317.84M$339.05M$398.78M$536.44M$647.84M$789.26M$996.13M$1.20B
Surprise %-0.04%-0.52%0.55%0.16%-----

Net Income Forecast

$-350M $-190M $-30M $130M $290M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-276.85M$-250.46M$-236.57M$-151.58M-----
Avg Forecast$-301.47M$-213.45M$-244.79M$-151.58M$-58.06M$39.08M$145.28M$284.60M$427.01M
High Forecast$-315.14M$-256.14M$-293.75M$-181.90M$-81.01M$27.97M$97.40M$253.84M$416.48M
Low Forecast$-288.89M$-170.76M$-195.83M$-121.27M$-35.10M$52.44M$224.33M$312.87M$435.79M
Surprise %-8.16%17.34%-3.36%------

FOLD Forecast FAQ

Is Amicus Therapeutics stock a buy?

Amicus Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Amicus Therapeutics is a favorable investment for most analysts.

What is Amicus Therapeutics's price target?

Amicus Therapeutics's price target, set by 7 Wall Street analysts, averages $15 over the next 12 months. The price target range spans from $15 at the low end to $15 at the high end, suggesting a potential 53.37% change from the previous closing price of $9.78.

How does Amicus Therapeutics stock forecast compare to its benchmarks?

Amicus Therapeutics's stock forecast shows a 53.37% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and underperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Amicus Therapeutics over the past three months?

  • February 2025: 8.33% Strong Buy, 66.67% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 7.69% Strong Buy, 69.23% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 14.29% Strong Buy, 64.29% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.

What is Amicus Therapeutics’s EPS forecast?

Amicus Therapeutics's average annual EPS forecast for its fiscal year ending in December is $-0.21 for 2024, a -99.96% decrease from the reported $-514 in 2023. The prediction for 2025 is $0.13, $0.46 for 2026, $0.97 for 2027, and $1.45 for 2028.

What is Amicus Therapeutics’s revenue forecast?

Amicus Therapeutics's average annual revenue forecast for its fiscal year ending in December is $528.08M for 2024, a 32.23% increase from the reported $399.36M in 2023. The forecast for 2025 is $637.75M, $785.14M for 2026, $983.62M for 2027, and $1.18B for 2028.

What is Amicus Therapeutics’s net income forecast?

For its fiscal year ending in December, Amicus Therapeutics's average annual net income forecast is $-58.056M for 2024, reflecting a -61.70% decrease from the reported $-152M in 2023. The projection for 2025 is $39.08M, $145.28M for 2026, $284.6M for 2027, and $427.01M for 2028.